Editas Medicine Launches $125M Share Offering After 90% LDL Reduction in Primates
EDIT•Cowen & Co reiterated its Buy rating for Editas Medicine after data showing a single dose of EDIT-401 reduced LDL-cholesterol by approximately 90% in non-human primate models. The company launched a 55.5 million share offering with $2.25-priced warrant units to raise $125 million, with potential $194.4 million more upon full exercise.
1. Cowen Reiterates Buy Rating
Analyst firm Cowen & Co maintained a Buy rating on Editas Medicine, emphasizing confidence in the company’s genome editing platform and the commercial potential of its lead candidate, EDIT-401.
2. EDIT-401 Preclinical Data Shows 90% LDL Reduction
In non-human primate studies, a single dose of EDIT-401 achieved mean reductions of approximately 90% or greater in LDL-cholesterol and other harmful lipids, supporting its development as a one-time treatment for hyperlipidemia.
3. Public Offering to Raise $125M
Editas launched a public offering of 55.5 million common shares with accompanying warrants priced at $2.25 per share unit to generate $125 million in gross proceeds, and warrants exercisable for 55.5 million additional shares could bring in $194.4 million more if fully exercised.
